Philip Boudreau compensation by year
ABBOTT LABORATORIES Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $513,943 | $884,039 | $974,231 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $786,041 | $2,693,071 | $3,045,935 |
| Option awards | $786,272 | $2,693,336 | $3,046,350 |
| Non-equity incentive | $583,500 | $1,224,700 | $1,055,400 |
| Pension and deferred compensation | $603,343 | $655,852 | $894,302 |
| All other | $44,083 | $74,748 | $74,418 |
| Total | $3,317,182 | $8,225,746 | $9,090,636 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ABBOTT LABORATORIES DEF 14A filed March 13, 2026, accession 0001308179-26-000064, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 22,495 | $2,818,399 | — |
| RSU | 15,349 | $1,923,076 | — |
| RSU | 1,618 | $202,719 | — |
| RSU | 874 | $109,503 | — |
| Option | 3,408 | — | $103.18 |
| Option | 83,783 | — | $135.42 |
| Option | 24,938 | — | $117.58 |
| Option | 29,020 | — | $87.72 |
| Option | 25,613 | — | $124.04 |
| Option | 6,383 | — | $106.24 |
| Option | 57,680 | — | $116.98 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ABBOTT LABORATORIES's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed March 13, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-01 | Tax withholding | — | 388 | $110.36 | 70,784 |
| 2026-04-23 | I | — | 8,909 | $92.04 | 9,276 |
| 2026-04-23 | Purchase | — | 2,200 | $91.50 | 2,200 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ABBOTT LABORATORIES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Robert Ford | Chairman of the Board and Chief Executive Officer | $24,198,660 |
| Philip Boudreau · this page | Executive Vice President, Finance and Chief Financial Officer | $9,090,636 |
| Lisa Earnhardt | Executive Vice President and Group President, Medical Devices | $8,069,724 |
| Hubert Allen | Former Executive Vice President, General Counsel and Secretary | $6,995,583 |
| Christopher Scoggins | Executive Vice President, Diabetes Care | $6,601,667 |
| Daniel Salvadori | Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | $6,534,285 |
The full ABBOTT LABORATORIES compensation record
free company briefThis page is one person within ABBOTT LABORATORIES's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ABBOTT LABORATORIES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ABBOTT LABORATORIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat